Estrogen Therapy in Non-severe COVID-19 Patients

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the effect of additional estradiol estrogen therapy on clinical response and mortality in non-severe COVID-19 patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CMN "20 de Noviembre"
• Treatments: Estradiol; Estrogens; Ethinyl Estradiol

Criteria

Inclusion Criteria:

• Male ≥ 18 years of age and female ≥ 55 years of age

• Diagnosis of positive SARS-CoV-2 infection confirmed by clinical diagnosis and / or RT-PCR test

• Hospitalized patients in acute disease* stages of the disease

• Agree to participate in the study prior to signing an informed consent.

• Patients with conventional treatment with anticoagulants (Noxaparin)

• Acute disease: patients who are hospitalized, conscious, not intubated, with biochemical values of D-Dimer> 2, Ferritin> 1000 u.

Exclusion Criteria:

• Patients with abnormal genital bleeding

• Patients with protein C or protein S deficiency

• Patients with liver failure (cirrhosis, hepatitis C)

• Patients with history of allergic reaction to estrogens use

• Patients receiving lamotrigine therapy

• Patients with a history of breast cancer and / or endometrial cancer

• Patients with severe hypoxia at risk of acute intubation in ED

• Patients with a history of cerebrovascular history

• Male patients with testosterone treatment

• Patients with a history of myocardial infarction, who have cardiac stents and / or unstable angina pectoris

• Patients with previous hormonal treatment